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Environmental chemicals are both activated and detoxified by phase Iand phase II enzymes. The principal enzymes
involved inphase IreactionsarethecytochromeP-450s. ThephaseBenzymesincludehydrolaseandtheconjugativeen-
zymessuchasglucuronyltransferases, glutathionetransferases,N-acetltransrase, andsulfotransferase. Althoughother
phase I and phase IIenzymesexist, the present review islimited totheseenzymes. Oncethought to be asingle enzyme,
multiplecytochromeP450enzymeshavebeenpurifiedandcharacterizedfrommanydifferentspeciesacrosstheevolu-
tionary tree. Theapplicationofmolecularbiobl techniquestothisfieldhasidentifiedmorethan 150cytochromeP450
genestodate. Atleast20-30cytochromeP450enzymesappeartoexistineachmammalianspecies,andmany polymor-
phismsintheseenzymesarebeingidentified. ThecytochromeP450enzymescannowbeexpressedinrecombinantform
usingcDNAexpressionsystems. ThephaseBconjugativeenzymesaddahydrophilicmoietysuchassulfate,glucuronide,
oracetate tocompounds, whichincreasestheirwatersolubility andfacilitatestheirexcretion. However,conjugates ofa
numberofcompoundsalsoresult inmoremactiveelectrophilic species, whichappeartobetheultimatecarcinogens Many
ofthese phaseIIenzymesalsorepresentfamiliesofenzymes,andpolymorphismscanaffecttheabilityoftheseenzymes
tometabolize chemicals. Whenever possible, wehave reviewedknowledgeofthehumanenzymesinvolvedin particular
pathways.
Introduction
Organisms have always been exposed to environmental
chemicals, and they have developed a variety of enzymes to
transform these "xenobiotics." The majority ofenvironmental
chemicals are highly lipophilic and cannot readily be excreted
fromthebody without metabolism to morehydrophilic, water-
soluble species. Metabolic pathways have therefore evolved to
converttheselipophiliccompounds towater-solublemetabolites.
The initial reaction(s) (phase Imetabolism) usuallyinvolvesthe
introduction ofoxygen into acompound asthefirst steptoward
detoxification and elimination (1). The principal enzymes
responsible for phase I reactions are the cytochrome P-450s,
although other enzyme systems such as the flavin-containing
monooxygenase, alcohol dehydrogenases, and prostaglandin
synthetase may also servethis functionforcertain substrates. The
hydrophilicityofthemetabolite canthenbefurtherincreasedby
phase II reactions. During phase II metabolism, various
membrane-bound and cytosolic enzymes, including epoxide
hydrolases (2,3), glutathione S-transferases (4), UDP-glu-
curonosyltransferases (5,6), acetyltransferases (7,8), and
'Laboratory of Environmental Risk Analysis, National Institute of Envi-
ronmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC27709.
2Division of Experimental Therapy, Burroughs Wellcome Co., Research
Triangle Park, NC 27709.
Address reprint requests toJ. A. Goldstein, National InstituteofEnvironmental
Health Sciences, P.O. Box 12233, Research Triangle Park, NC27709.
sulfotransferases (9), attach highly water-soluble moieties to
polargroups(oftenthoseintroducedbyphaseIreactions). The
net result of the combined phase I and phase II reactions is
generally todetoxify andeliminate environmental xenobiotics
fromthebody. However, thesesamepathwayscanalsocarryout
theactivationofmosttoxicandcarcinogenicchemicalstoelec-
trophilic forms which can react irreversibly with macromole-
cules such as proteins and nucleic acids. The importance of
metabolism intheactivationofcarcinogens wasfirstrecognized
by Miller and Miller (10,11) in their pioneering studies on the
metabolism ofthe aminoazo dyes and 2-acetylaminofluorene.
Themajorityoftheseelectrophilesareformedbythecytochrome
P450-dependentenzymes, although somephaseIIconjugations
produce theultimate carcinogen for certain chemicals (1).
The microsomal cytochrome P-450 enzymes were first
reportedbyKlingenbergin 1958(12),whonotedthecharacter-
istic carbonmonoxidedifference spectrumofmicrosomeswith
amaximumnear450nm, which is now known tobeduetothe
axialthiolateligationofhemewithaconservedcysteineresidue
intheP450apoprotein. OmuraandSato(13)providedevidence
thatthepigmentwasab-typecytochromeandproposedthename
"P-450" todenoteapigmentwithabsorption at450nm. They
alsopartiallypurifiedthepigment, determineditwasahemopro-
tein, and measured its extinction coefficient (14,15). A
physiological function for this pigment was first reported by
Estabrookandco-workers(16,17), whofoundthatitparticipated
in the C21 hydroxylation carried outby adrenal cortex micro-GOLDSTEINANDFALE7TO
somesandthehydroxylation anddealkylations ofvariousdrugs
by liver microsomes. Another important development was the
finding ofConney andBurns (18,19)thatadministrationofdrugs
toanimals could inducedrug-oxidizingactivitiesofmammalian
liver microsomes. This could be explained by increases in the
cytochromeP-450 contentoflivermicrosomes ofdrug-treated
animals.
Cytochrome P-450wasoriginallythoughttobeoneenzyme.
However, when phenobarbital and 3-methylcholanthrene
(3-MC) wereadministeredtoanimals, theyhaddifferenteffects
ontheoxidationofvarious drugsby livermicrosomes. In 1967,
Conney (19)proposedthatinduciblecytochrome P-450s could
becharacterized aseitherphenobarbital- or3-MC-like. Sladek
and Mannering (20) alsoreportedevidenceforthepresenceof
a different form ofcytochrome P-450 in liver microsomes of
3-MC-treated rats than incontrol orphenobarbital-treated rats.
The 3-MC-inducible cytochrome hadanabsorption maximum
of448 nmcomparedto450nm forthephenobarbital-inducible
form and could be distinguished by differences in the pH
dependency ofits ethyl isocyanide spectrum. Thiscytochrome
was called cytochrome P,-450 or P-448. However, there was a
controversy for several years as to whether there was a single
form ofcytochrome P-450 or multiple forms ofthis enzyme.
Initial attempts topurifycatalyticallyactivecytochromeP-450
were unsuccessful due to the instability ofthis enzyme in the
presence ofthedetergents used forsolubilization. However, in
amilestone study, LuandCoon(21) wereableto solubilizeand
fractionatecytochromeP450, NADPH-dependentcytochrome
P-450 reductase, and a lipid fraction using DEAE-cellulose
chromatography in the presence ofglycerol and subsequently
reconstitutecatalytic activity. Withtheavailabilityoftechniques
forpurification, it soonbecameapparentthatmultiple formsof
cytochrome P-450 existed in each species (22,23). The cyto-
chromes P450arenowknowntocompriseasuperimunilyofpro-
teins, each with a characteristic spectrum of substrate
specificities (seebelow). Someofthese forms areconstitutive,
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others are inducible by phenobarbital, 3-methylcholanthrene,
certain steroids, ethanol, or peroxisome proliferators such as
clofibrate (23,24). The cDNA and gene structure of many of
these P-450s have been elucidated (25). These proteins have
beengroupedintofamilies andsubfarmilies basedon similarities
inprotein structure. Individualcytochrome P-450enzymes are
defined as belonging to the same family ifthey are more than
40% similarinaminoacidsequence, andwithinasubfamily are
>59% identical. The cytochrome P-450s are named with the
rootCYPfollowedbyanarabic numeral forthefamily, acapital
letterforthe subfamily, andanarabic numeral fortheparticular
gene. More than 150 cytochrome P-450 genes have been char-
acterized todate, and 10 families exist in mammalian species.
Someofthesefamilies areresponsibleforthemetabolismofen-
dogenous compounds, including the stereo-specific synthesis of
steroids from cholesterol and the subsequent metabolism of
steroids. Three families (CYPI, 2, and 3) represent thehepatic
mixed-function oxidases, which metabolize primarily xeno-
biotics and may have evolved in response to environmental
stresses such as plant toxins and environmental compounds
derived from combustion.
Phase I Reactions
As discussed above, the phase I monooxygenase system has
beenresolvedintothreemain components: cytochrome P-450,
NADPH-cytochrome P-450 reductase, and lipid. Cytochrome
P450actsastheterminaloxidaseinthissystemandcatalyzes the
insertion of one atom of molecular oxygen into a substrate
(monooxygenase) toconvertthesubstratetoamorepolarcom-
pound, whileconvertingtheotheratomofoxygenintowater, us-
ing electrons donated by NADPH via NADPH cytochrome
P-450reductase (Fig. 1). Inthegeneral reactionofcytochrome
P-450-mediated oxidation, theoxidized ferric formoftheP-450
firstinteractswith aspecific substrate. Subsequently, anelectron
is transferred from NADPH via the reductase to produce the
chrome P4503
Substrate Substrate
Cytochrome P450*3
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Cytochrome P4503
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Cytochrome P450+3-O
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FIGURE 1. General scheme for P450-mediated oxidation ofsubstrates.
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ferrous-P-450-substrate complex, whichthenbindsmolecular
oxygen. Aftertheoxidationoftheferrouscytochromebacktothe
ferric form, theoxygenbecomes "activated." Anotherelectron
is then transferred from NADPH via the reductase, and this
results inthestereo-specific oxidationofthesubstrate, formation
of water, and regeneration of the ferric form of cytochrome
P-450. The substrate-freeoxidized cytochromeP450 canthen
reenter the catalytic cycle.
Although awidevarietyofoxidativereactions aremediatedby
the cytochrome P-450-dependent monooxygenase system, the
majority of these reactions can be visualized essentially as
hydroxylations. Someexamples oftypes ofreactions catalyzed
by this system are shown in Figure 2 and are discussed below.
C-Hydroxylation. Aromatic groups can be hydroxylated or
epoxidized, sometimes resulting in the production of toxic
metabolites [reviewed by Guengerich and Shimada (1) and
Nelson and Harvison (26)]. Examples are metabolites ofben-
zene and polycyclic aromatic hydrocarbons. Aliphatic com-
pounds can also be hydroxylated. For example, n-hexane is
metabolizedtotheultimateneurotoxin, 2,5-hexanedionebythis
process. The C-hydroxylation ofN-nitrosodialkylamines pro-
duces unstable intermediates that rearrange to release reactive
carbonium ions, which are the ultimate carcinogens. The car-
bonium ions can methylate at oxygen or nitrogen atoms in the
purines andpyrimidines ofDNA.
N-Hydroxylation. The N-hydroxylation of arylamines and
acetylamines (such as benzidine, 4-aminobiphenyl, 2-acetyl-
aminofluorene [2-AAF],andheterocyclicarylaminesformedby
food pyrolysis) is a critical initial step in the production ofthe
ultimatecarcinogens. TheN-hydroxylamines areconsideredpro-
ximatecarcinogens becausethey aregenerally moremutagenic
andcarcinogenic thantheparentcompounds (27). Furthercon-
jugative processesdescribed laterinthis reviewleadtothepro-
duction of more electrophilic species, which are the ultimate
carcinogens.
S-Oxidation. As an example ofS-oxidation ofthionosulfur
compounds, theinsecticidephorateisoxidizedtotheS-sulfoxide,
which canbefurthermetabolized tothesulfoneandthephorate
oxon sulfone (28). Many of these sulfoxide metabolites are
cytotoxic (26).
Dealkylation. Dealkylations atnitrogen, oxygen, orsulfur are
alsocatalyzedbythecytochrome P-450enzymes. Examples of
these reactions includetheO-dealkylationofvariousdrugs such
asphenacetin toacetaminophen (reaction shown inFig. 2), the
N-demethylation of aminopyrine, and the S-dealkylation of
6-methylthiopurine to6-mercaptopurine. Aminescanalsobeox-
idatively deaminatedby asimilarprocess (notshown), whichis
primarily adetoxification process.
EpoxidationatOlefinicCenters. Olefiniccompoundssuchas
styrene, haloalkenes such as vinylidene chloride and trichlo-
roethylene, anddihydrofurans such asaflatoxin areactivated at
thecarbon-carbon 7r-bondbyepoxidation (26). Manyofthese
epoxides canreactwithcellularmacromoleculesandaregeno-
toxic. These reactions can also result in the alkylation and
suicide-based inactivation of the heme group ofcytochrome
P-450.
Oxidative and Reductive Dehalogenation. A variety of
halogenated alkanes, alkenes, and alkynes are oxidized at the
carbon-hydrogen bond to produce unstable intermediates that
dehalogenate to formaldehydes orketones (26). Examples are
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FIGURE 2. Examples ofactivation and deactivation pathways for xenobiotic
metabolism by cytochrome P-450enzymes.
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the oxidation ofethylenedibromide to2-bromacetaldehyde and
theoxidationofchloroform tophosgene. Themetabolitesofthe
mono- anddihalomethanes areonly weakly cytotoxic. However,
trihalomethane metabolitessuch asphosgeneproducehepatotox-
icity and renal toxicity. Thetetrahalogenated methanesproduce
toxicity by adifferent mechanism. These compounds undergo
reductive dehalogenation to produce a free radical. Carbon
tetrachloride produces both hepatic and renal damage via this
mechanism.
HumanCytochrome P-450 Enzymes In-
volved in the Activation of Chemicals
Many ofthe human P450 enzymes were first isolated in the
laboratory of Guengerich and co-workers (1). The advent of
cloning hasallowedcomparisonofthededucedaminoacid struc-
tures ofthe various enzymes (25). Itis possible toestimate the
point in the evolutionary scale that proteins diverged based on
their percenthomology. Some cytochrome P-450 enzymes are
very old andapparently evolvedbeforethedivergenceofhumans
and rodents. Inthis respect, analogs forcytochromes P-450 lAl
and P-450 1A2 have been found in all mammalian species
studied. Thesecytochromes are induciblebychemicals such as
3-MC and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) via a
receptor-mediated mechanism [the Ah receptor; reviewed in
Gonzalez (24)]. P-450 lAI appears to be important in the
metabolic activation ofpolycyclic aromatic amines inall species
examined (1). P-450 lAl is notfound or isonly present in small
concentrations in human liver (29,30), but it is inducible by
polycyclic hydrocarbons inextrahepatictissues such aslung (31).
In contrast, P-450 1A2 is present in human liver but not ex-
trahepatic tissues and appears to be more active in the N-
hydroxylationofarylamines inbothhumansandrodents (29,32).
ManyotherformsofhumancytochromeP-450 involvedinthe
oxidationofxenobioticsdo not appeartohave exactcounterparts
in laboratory animals (theCYP2A, 2B, 2C, 2D, 3A, and4A sub-
families). Therefore, the different species may have diverged
beforetheevolution ofthesubfamiliesfromancestral forms. The
various cytochrome P450 genes areassigned to subfanmilies bas-
ed on their amino acid sequence homologies; however, the
catalytic specificity determined for apparent P-450 homologs
acrossspecies are notalways identical. Inaddition, recentstudies
by Negishi andco-workers (33) have shown that asingle amino
acid substitution convertsthesubstratespecificityofP-450coh
to P-450 15a(fromcoumarin tosteroid 15a-hydroxylase). These
studies clearly indicate that it is impossible topredict substrate
specificity across species.
More than 20 cytochrome P-450s have been identified in
humans. Many membersoftheCYP2CandCYP2D families ap-
pear to be involved in the metabolism of clinically important
drugs(24). TheseP-450salsoexhibitalargedegreeofpolymor-
phism inexpression, which maybeimportantforinterindividual
differences in susceptibility to exposure to environmental tox-
icants ortherapeutic agentsmetabolizedby theseP-450s. For ex-
ample, P-450 2D6 metabolizes the antihypertensive drug de-
brisoquine. Apolymorphism intheexpression ofthis gene has
been described (34). There are multiple mechanisms for this
polymorphism, but a predominant mechanism is an abberant
splice recognition site(35). Acorrelationbetweensusceptibility
tolungcancerandthepoordebrisoquinemetabolizerphenotype
has been suggested (36). However, this association has been
questioned inotherstudies (37), andthere is noknownexample
ofacarcinogenmetabolizedappreciably by P-4502D6 (1). Itis
notyetclearwhethertheCYP2CorCYP2D subfamilies are im-
portantintheactivationofchemical carcinogens inhumans (1).
P-4502E1 isanethanol-inducible formthatcatalyzestheox-
idation ofethanol to acetaldehyde. It also appears to be impor-
tant in the activation of methyl substituted N-nitrosamines in
rodents and humans (1). However, it does not appear to con-
tribute to the oxidation of tobacco-specific nitrosamines or a
numberofothernitrosamines. Recently Guengerichetal. (38)
haveprovidedevidencethathumanP-4502E1 is important inthe
metabolismoflow molecular weightsuspect carcinogens such
as vinyl chloride, vinyl bromide, benzene, styrene, carbon
tetrachloride, ethylene dibromide, trichloroethylene, ethylene
dichloride, methylene dichloride, 1,2-dichloropropane and
1,1,l-trichloropropane.
Inhumans, the P-450 3A subfamilycontainsthreemembers.
Thepredominantform, P-4503A4, appearstoplayamajorrole
in the oxidation of many steroids including testosterone, an-
drostenedione, progesterone, and cortisol (1). These are
substrates whicharemetabolizedbyothersubfamilies(P-4502B,
P-450 2C) in rodents (23). Human P-450 3A4 also appears to
play amajorroleintheactivation ofaflatoxinB1, thefire retar-
danttris(2,3-dibromopropyl)phosphate, 6-aminochrysene, and
anumberofpolycyclichydrocarbondihydrodiolsthatcanbecon-
verted to bay-region diol epoxides (1). This enzyme can also
deactivatecertain substrates, includingalternateoxidative detox-
ification pathways for aflatoxin B1.
Phase 11 Reactions
Epoxide Hydrolases
Epoxides arereactivemetabolites thataregeneratedprincipal-
ly by the cytochrome P-450 dependent pathways. The epoxide
hydrolases areconsideredtobeprotectiveenzymesthathydrate
theepoxidesto formtrans-1,2-dihydrodiols. Theseless reactive
dihydrodiols can then be conjugated with glucuronic acid,
sulfate, orglutathione andexcreted. Themetabolismofbenzene
viathesepathwaysisshowninFigure3. However,theactivity of
epoxidehydrolasecanalsoresultintheproductionofmorereac-
tivespecies, asinthehydrolysisofbenzo[a]pyrene-7,8-oxide to
its dihydrodiol, which is then metabolized by P-450 to the
ultimatecarcinogen, benzo[a]pyrene-7,8-dihydrodiol-9,10-epox-
ide(39). Therearemultipleformsofepoxidehydrolase(3). The
twoformsthatmetabolizexenobioticsaremicrosomalepoxide
hydrolase (mEH) and cytosolic epoxide hydrolase (cEH). The
mEHmetabolizesawidevarietyofsubstrates, includingbothK-
region and non-K region arene oxides ofpolycyclic hydrocar-
bons, butadiene, vinyl chloride, epoxides derived from her-
bicidesandinsecticides, andepoxidesderivedfromtherapeutic
drugssuchasphenytoin. Bay regiondiol-epoxidesofpolycyclic
hydrocarbons, on the other hand, are poor substrates. Micro-
somalepoxidehydrolasealsohas asmall roleinthedetoxifica-
tionofaflatoxinB1 8,9-oxide, themajorspeciesresponsiblefor
thegenotoxicity ofaflatoxinB. Thesecompounds aredetoxified
primarily by glutathione conjugation. Cytosolic epoxide hy-
drolase is found primarily in the cytosol and peroxisomes. It
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FIGURE 3. Summary of some ofthe phase II routes of metabolism ofbenzene including epoxide hydrolase, sulfotransferase, glucuronidation, and glutathione
transferase. UDPGA (uridinediphosphoglucuronic acid) isthecofactorforglucuronosyltransferase. PAPSisthecofactor(adenosine3 '-phosphate 5'-phosphosulfate)
for sulfotransferase.
specifically catalyzes thehydrolysis ofmono- and disubstituted
oxiranes, but does not metabolize arene oxides appreciably.
Substrates includetrans-substituted styreneoxides, stilbene ox-
ides, and lipidepoxides (e.g., epoxidederivativesofarachidonic
acid).
Epoxidehydrolase hasbeen found inallorganisms examined
to date, including fungi. However, mEH and cEH can be clas-
sified only inhigherorganisms. The enzymes havebeen purified
from a number of species including humans. Although the
highest activity ofboth mEH and cEH is found in the liver, the
organdistributionofmEH isquite broad. Oesch andco-workers
(40) found considerable interindividual variability in the ac-
tivities ofthese two enzymes in human liver (from 63-fold for
mEH to 539-fold forcEH). cDNAs forratand humanmEH have
beenisolated, andhybridization studies indicatethatthereisonly
one gene copy of mEH in the human and the rat (2). Hepatic
mEH is inducible in ratsby both phenobarbital and 3-MC type
inducers, whilecEHisinduciblebyperoxisomeproliferators (3).
Glutathione S-Transferases
There are multiple forms ofthe soluble glutathione S-trans-
ferases, which can be divided into four gene families based on
theirelectrophoretic mobilities (4,41). Thea-Egroupconsists of
basic proteins,ta is a neutral class, and the Xr enzyme is acidic.
The microsomal membrane-bound glutathione S-transferase
represents anunrelated enzyme. Glutathione S-transferases are
found in almost all tissues examined. These enzymes transfer
glutathione (thetripeptide -y-glutamyl cysteinyl glycine) to com-
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FIGURE 4. Activation ofethylene dibromide by glutathione transferase.
pounds that areelectrophilic perseaswellasthosegeneratedby
phase I reactions. Thus, glutathionetransferases canplay apro-
tective role by covalently binding and removing reactive elec-
trophiles. Examples are the detoxification ofbenzene epoxide
(Fig. 3), aflatoxin B,-8,9-oxide, and benzo[a]pyrene-7,8-di-
hydrodiol-9,10-oxide. However, some procarcinogens are ac-
tivatedbyconjugationwithglutathionetoproduceunstablereac-
tive metabolites (41). Examplesofsuchgenotoxic metabolitesare
the glutathioneconjugatesofethylenedibromide andmethylene
chloride (Fig. 4). The A form is found inthe liversofonly 60%
ofthehumanpopulation(4). Thisformisefficientinconjugating
epoxidesofbenzo[a]pyrene4,5-oxide. Ithasbeensuggestedthat
a hereditary polymorphism of the j4 form may be related to
susceptibility to lung cancer among cigarette smokers (42).
UDP-Glucuronosyltransferases
Uridinediphosphate glucuronsyltransferases represent ama-
jor phase II family ofendoplasmic reticulum-bound enzymes
that utilize the cofactor uridine diphosphoglucuronic acid
(UDPGA) to conjugate glucuronic acid to a large number of
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potentially reactive compounds including phenols, dihydrodiols,
quinones, and quinols (5,6). The addition of glucuronic acid
renders these compounds more water soluble and enables the
body to excretethem more readily. Examples ofsubstrates that
are conjugated with glucuronic acidby this system include the
phenols, dihydrodiols, quinones, andquinols ofnumerouscom-
pounds such as benzene (Fig. 3), benzo[a]pyrene, and the
chlorinated benzenes. Conjugates can include ether O-glu-
curonides, ester O-glucuronides (glucuronic acid groups), N-
glucuronides, S-glucuronides, and C-glucuronides. Although
glucuronidationisamajorrouteofdetoxification formanycom-
pounds, glucuronidation isinvolvedintheetiologyofhumancol-
orectal cancerfromheterocyclic amines. Thesecompounds are
first N-oxidated and then N-glucuronidated. The N-hydroxy
metabolites can be transported to the colon where they are
hydrolyzedbyf-glucuronidases. TheN-hydroxyderivatives can
thenbe O-acetylated in thecolon mucosa, which results in for-
mation ofN-acetoxyarylamines which can react with DNA to
form covalent adducts (43).
Acetylation
Acetylation involves the enzymaticor nonenzymatic transfer
ofthe acetyl group fromacetyl coenzyme A to molecules con-
taining a primary amine, hydroxyl, or sulthydryl group (7).
These enzymes aredistributed in many organs, butthe liver isa
major site ofN-acetylation. Acetylation ofthe primary amine
group of arylamines and hydrazines is a major route of
biotransformation ofthesecompounds. Arylamidesandprimary
arylamines are interconverted by N-acetyltransferases and
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FIGURE 5. Acetylation and sulfation ofarylamines to putative mutagenic and carcinogenic metabolites (metabolites I-V).
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deacetylases(27). Theyareinitially activatedbythecytochrome
P-450s and flavin monooxygenase enzymes to form N-hydro-
xyarylamides and N-hydroxyarylamines that can be inter-
converted by enzymatic N-deacetylation/N-acetylation (Fig. 5).
These compounds are considered proximate carcinogens
because they are more mutagenic and carcinogenic than the
parentcompounds. N-Hydroxyarylamides areconvertedtothe
ultimatecarcinogens throughconjugationwithsulfuric, acetic,
orglucuronic acids. N-acetoxyarylamines (metabolite II inFig.
5) are highly reactive and appear to have an important role as
ultimatecarcinogens. Therefore, O-acetylation appearstoplay
an importantrole intheactivation ofaromatic amines andfood
pyrolysates classified as human carcinogens, including 2-
aminofluorene, benzidine, 4-aminobiphenyl, and ,B-naphth-
ylamine.
There is a polymorphism in acetylation in humans, with the
population beingdivided into slow andrapidacetylators. Meyer
andco-workers(44)haveclonedthegenesNA71 andNA72, that
encodetwoproteinswithN-acetyltransferase activity whenex-
pressed inculturedmammaliancells. TheNA12geneisthegene
which showsthe polymorphism. There appear tobe three ma-
jor mutant alleles in Caucasian populations, which consist of
single aminoacid mutations.
Acetylationmayaffectthecarcinogenicity ofaromaticamines
intwoways. Inbladdercancer, acetylationappearstobeadetox-
ification mechanism for aromatic amines such as 2-naph-
thylamine and benzidine. Epidemiological studies in various
populations including workersinthedyeindustryhavefoundthat
bladdercancerismorecommonintheslowacetylatorphenotype
thantherapidacetylatorphenotype (45,46). Ontheotherhand,
epidemiological studies indicate that slow acetylators have a
decreased riskforcolorectal cancer (47), presumably because
theglucuronides ofaromatic amines arehydrolyzed inthecol-
on, andthenacetylatedtoreactiveN-acetoxyarylamines incol-
on mucosa as discussed earlier. Studies ofthe aromatic amine
2-aminofluorene indicate that acetylation and sulfation yield
morereactiveelectrophiles whichreactwithnucleicacidstopro-
duce adducts (8).
Sulfation
Sulfate conjugation improves watersolubility andexcretion.
The sulfotransferases are a family ofenzymes thattransfer the
sulfuryl group (SO3) from adenosine 3'-phosphate 5'-phos-
phosulfate (PAPS) tohydroxyl oramino groups (Figs. 3 and 5)
(9,27). Sulfotransferasesarewidespread intissues, withhighac-
tivitiesfoundinplatelets,erythrocytes, thejejunum, brain, liver,
andplacenta. They arefoundinboththecytosolandendoplasmic
reticulum. Conjugation with sulfate is generally considered a
detoxificationmechanism. However, theadditionofsulfatealso
introduces agoodleavinggrouponunstablecompounds suchas
hydroxylamines (Fig. 5). TheN-sulfonyloxy derivatives arecon-
sidered to be among the predominant metabolites of
2-acetylaminofluorene responsible fortheformationofDNAad-
ducts and itscarcinogenicity.
Future Studies
Originally, only a single form of cytochrome P-450 was
thought to exist. However, it has become apparent that the
cytochromeP-450enzymes representavastsuperfamily ofen-
zymes. Inrecentyears, anumberofapproaches tostudying the
role ofthese enzymes in the metabolism ofvarious substrates
havebeenparticularlyuseful. Techniques forpurificationofthe
P-450 enzymes and reconstitution of the complete enzyme
systems havebeen developed. Antibodies have been utilized to
quantitate isozymes and to inhibit specific catalytic pathways.
Antibody inhibition studies using microsomes fromparticular
humantissuesareparticularlyuseful forassessingthecontribu-
tionofa P-450 form to aparticular pathway.
Molecularbiologytechniques haveclarified someofthecon-
fusionconcerningthemultiplicityofthecytochromeP-450fami-
ly, andtheuseofcDNAexpressionsystemsallowsinvestigators
to examine the catalytic activity of specific isozymes. Minor
changesinaminoacidsequencecanproducedramaticeffectson
the catalytic activities or even the substrate specificities ofin-
dividual P-450enzymes. Therefore, the substrate specificity of
humanenzymescannotbesimply inferredfromanimal studies
orstudieswithrodentP-450s. cDNAexpressionstudiesarepar-
ticularly useful indetermining theintrinsic abilityofparticular
cytochrome P-450 enzymes to activate mutagens, and the
availability of cDNAs for multiple human forms provides a
means for studying theability ofaparticular human P-450 (or
conjugativeenzyme) toactivatespecificchemicals. Site-directed
mutagenesisstudiesallowscientiststoprobetheactivesitesand
determine which portions of the enzyme are important in
substrate binding and catalytic activity. However, activity in a
recombinantcell line may notduplicate the enzymatic activity
inhumanliver; therefore, studieswithhumanlivermicrosomes
and antibodies to human cytochromes remain necessary.
Bacterial cDNA expression systems will also be useful in the
future forpurifying largeamounts ofrecombinanthuman pro-
teins that werepreviously difficult to isolate.
ManyofthecytochromeP-450enzymesarepolymorphic and
therelationship between polymorphisms and cancer is an area
of active research between molecular biologists and epi-
demiologists. Themolecularbiologyofsomeoftheconjugative
enzymeshasnotbeenstudiedasextensively asthatoftheP-450
enzymes, butrecentstudieshavebeguntoaddressthesefamilies.
Thereisclearevidenceforpolymorphisms inoneoftheenzymes
involved in acetylation in humans. Information regarding the
abilityofspecificmetabolitestoformDNAadductsandtherela-
tionshipoftheseadductsto cancerisvital tounderstanding the
role ofmetabolism in the etiology ofenvironmentally induced
cancer.
Theauthorsaregrateful to L. TomBurka, National InstituteofEnvironmen-
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